key: cord-0969824-xlqb71it authors: Zecher, Britta Franziska; Buescher, Gustav; Willemse, José; Walmsley, Martine; Taylor, Alison; Leburgue, Angela; Schramm, Christoph; Lohse, Ansgar W.; Sebode, Marcial title: Prevalence of COVID‐19 in patients with autoimmune liver disease in Europe: A patient‐oriented online survey date: 2021-06-09 journal: United European Gastroenterol J DOI: 10.1002/ueg2.12100 sha: 3472dd1d4bb6bca93174648b9a7c1c2b0ed5c6d4 doc_id: 969824 cord_uid: xlqb71it BACKGROUND: During the current SARS‐CoV‐2 pandemic it is important to identify risk factors for COVID‐19. Registry studies are providing growing evidence on the elevated risk of mortality from COVID‐19 in patients with chronic liver disease, especially in advanced stages. Results may, however, have a selection bias towards severe cases. Limited data is available on COVID‐19 in patients with autoimmune liver disease (AILD). AIM: To perform an online survey to capture the prevalence of COVID‐19 and the state of medical care of patients with AILD in Europe during the pandemic. METHODS: Data was collected via an anonymous patient‐oriented, online survey, which was available on the EUSurvey platform in nine European languages between 24(th) June 2020 and 14(th) October 2020. Of 1834 contributions, 51 were excluded because participants did not name an underlying AILD, and four were excluded because of duplicate data entry. RESULTS: Of 1,779 participants, 1,752 resided in 20 different countries of the European Union and the United Kingdom (UK). The five countries with the highest numbers of contributions were France (n = 450), Germany (n = 318), the Netherlands (n = 267), Spain (n = 225), and the UK (n = 183). 2.2% of participants (39/1779) had been diagnosed with COVID‐19. There were no differences regarding age, sex, AILD, the status of liver cirrhosis, or status post liver transplantation between COVID‐19 and non‐COVID‐19 cases. Of the 39 COVID‐19 cases, five patients were admitted to a regular ward, one patient was admitted to ICU and required ventilation. CONCLUSION: In our Europe‐wide, patient‐oriented survey on COVID‐19 in patients with AILD, we detected a low rate of COVID‐19, comparable to the period prevalence of the general population. These results suggest that patients with AILD are not at elevated risk of COVID‐19. Arising from a cluster of pneumonia of unknown etiology in December 2019 in Wuhan, China, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 , has developed into a worldwide pandemic. 1, 2 Identifying patients at risk of severe courses of COVID-19 has gained major importance in order to protect vulnerable individuals, preserve the resources of health care systems, and guide patient counseling. Risk factors for a severe course of COVID-19 that have been identified in the past months include male sex, age over 65, smoking, diabetes, arterial hypertension, and chronic cardiovascular, renal, and respiratory disease. [3] [4] [5] The role of autoimmune diseases and immunosuppressive treatment as potential risk factors is still under investigation. The three autoimmune liver diseases (AILD), autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC) are rare, but cause a notable disease burden accounting for about 11% of orthotopic liver transplantations in Europe between 1999 and 2009. 6 Most patients with AIH and patients with AILD after liver transplantation require lifelong immunosuppressive treatment. Furthermore, patients with liver cirrhosis independent of the kind of liver disease are regarded to be in a state of immune dysfunction. 7 These patient groups may be at risk of severe COVID-19. AILD is limited to regional observational studies driven by referral centers suggesting no increased risk of COVID-19 in patients with autoimmune hepatitis. 8, 9 However, patients with chronic liver disease, notably those with liver cirrhosis and a higher Child-Pugh score, seem to be at risk of decompensation of liver disease and death in the context of COVID-19. [10] [11] [12] Furthermore, an international registry study on patients with COVID-19 and chronic liver disease in Europe identified liver cirrhosis and alcoholic liver disease to be risk factors for mortality from COVID- 19. 13 Current registries on COVID-19 in patients with liver disease are based on data entry by treating physicians so reporting bias towards severe cases is likely. The primary aim of our study was to assess the incidence of COVID-19 in patients with AILD by directly addressing patients independent of their presentation to the health care system. We present the results of the first patient-oriented and Europe-wide survey on COVID-19 in patients with AILD. Data was collected via a patient-oriented, browser-based online survey (Text S1 (3) The study was also announced on the ERN RARE-LIVER webpage. In order to provide an estimation of response rate for this survey, the numbers of patients treated at ERN RARE-LIVER healthcare centers and being members of the above-mentioned patient organizations are provided in Table S1 . In accordance with the local ethics committee, no ethical approval was necessary for this anonymous online survey. Statistical analysis was performed using IBM SPSS Statistics 27. Chi squared (χ 2 ) test was used to compare two or more groups. Statistical significance was considered for p-values <0.05. The inclusion and exclusion criteria of the survey are displayed in Table 1 ). The most common AILDs were PBC and AIH (34.9% and 34.7% resp.), followed by PSC (20.2%) and by the variant syndromes PBC/AIH (6.3%) and PSC/AIH (3.8%). About 29% of participants indicated having cirrhosis and 7% of participants had received liver transplantation (Table 1) . There are known differences in the epidemiologic characteristics of the different AILDs, which may also lead to the differential distribution of risk factors for COVID-19. Therefore, we further characterized the cohort according to the underlying AILD. Age pattern was markedly different among the groups with 41.4% of participants diagnosed with PBC being 60 years old and older while only 18.9% of participants with PSC were 60 years old or older, (p ˂ 0.001 for differences in age pattern among the five AILD; Table 2 ). Analysis of medical treatment of AILD (Table S2 -S4) showed differences among the European countries. Furthermore, the kind of treatment of participants with concomitant IBD was analyzed (Table S5) . Out of 1,779 participants, 39 were diagnosed with COVID-19 (2.2%; Table 1 ). Most of the COVID-19 cases came from France (35.9%) and Spain (28.2%; Table 3 ). There were no significant differences in COVID-19 prevalence between the groups of AILD (PBC/AIH: 0%, PSC/AIH: 1.5%, PBC: 1.9%, AIH: 2.3%, PSC: 3.3%, p = 0.288, Table 2 ). Between COVID-19 cases (n = 39) and non-COVID-19 cases (n = 1730), there were no significant differences regarding age, sex, smoking, kind of AILD, status post liver transplantation, secondary diagnoses, or presence of liver cirrhosis ( Table 3) . Treatment of AILD did not differ significantly between COVID-19 and non-COVID-19 cases for most of the drugs. Only azathioprine or mercaptopurine was significantly more frequently taken by non-COVID-19 cases (26.4% vs. 10.3%, p = 0.023). Of the self-reported 39 COVID-19 cases, the diagnosis was confirmed by nasopharyngeal swab in 48.7% (19 cases; Table 4 ). The ZECHER ET AL. -3 majority of participants were diagnosed at the A&E department of a hospital (33.3%), followed by a general practitioners' office (30.8%). Five out of 39 cases were admitted to a regular ward of a hospital (12.8%) with a mean stay duration of 10.8 days (SEM 3.4 days). One participant was admitted to an intensive care unit and required mechanical ventilation. This participant was a 70-79-year-old woman with AIH, treated with predniso(lo)ne and azathioprine or mercaptopurine. She did not have liver cirrhosis or previous liver transplantation but had lung disease as comorbidity. Of the five patients, who had been admitted to a regular ward, three were treated with prednisolone, one with azathioprine or mercaptopurine, and three with UDCA ( Table 5 ). None of them received changes regarding AILD treatment, while 6.3% of COVID-19 cases who were not admitted to hospital received dose reduction of their AILD treatment (Table 5) . At the preliminary peak of the COVID-19 pandemic in Europe, outpatient healthcare was not always maintained at regular levels. reported to have suffered from cough, 11.5% from fever, 8.5% from shortness of breath, and 2.2% from smelling problems since January 2020. About 73% of participants did not report any of these symptoms (Figure 1a ). Of the non-COVID-19 cases, 16.3% received a SARS-CoV-2 test since January 2020 (Figure 1b) . Participants who reported fever or cough received a SARS-CoV-2 test significantly more often than participants without these symptoms (35.2% vs. 14.0% and 25.2 vs. 14.8%, p ˂ 0.001, Table S6) CoV-2 test significantly more often than cases without these contacts (Table S6 ). For most of the participants, medication was unchanged (85.4%), whereas medication was reduced in dosage or stopped for only a few participants (2.4% and 0.7% resp.; Figure 2a ). About 57% of participants did not feel well informed about their personal risk of COVID-19 by their treating physician (Figure 2b ). About 25% were told they were not at increased risk of COVID-19, while increased risk due to immunosuppressive treatment or the underlying liver disease was communicated to 19% and 8% of participants, respectively ( Figure 2c ). regions such as Lombardy (Italy) and Flanders (Belgium). 8, 9, 14 Total n = 1,730 Total n = 39 Total n = 1,730 Total n = 39 Spain, Italy, and the UK (5.4%, 2.5%, and 6.0% seroprevalence, resp.), the rate of COVID-19 based on self-reports in our study cohort was similar or even lower than those rates of the general national populations. 21 The comparison of COVID-19 versus non-COVID-19 cases among the participants did not show significant differences regarding previously described risk factors such as age, male sex, lung disease, arterial hypertension which is probably due to the small number of COVID-19 cases in our cohort (n = 39, 2.2% of participants). 3, 4 Chronic liver disease and liver cirrhosis have been suggested an increased risk of severe courses of COVID-19 for mycophenolate in a dose dependant manner. 24, 26 Association of systemic glucocorticoids and hospitalization or adverse events in patients with IBD or rheumatic disease and COVID-19 was reported. 27, 28 However, the use of dexamethasone seems to be beneficial in hospitalized COVID-19 patients requiring respiratory support. 29 In our cohort, there were no significant differences in the usage of glucocorticoids, calcineurin inhibitors, or mycophenolate mofetil between the COVID-19 and non-COVID-19 groups. For most of the survey participants, medication for AILD was unchanged during the pandemic. However, in the COVID-19 group, significantly fewer patients were treated with azathioprine or mercaptopurine during the COVID-19 pandemic, further studies with larger patient numbers are needed. As mentioned above, due to the small number of COVID-19 cases in our survey, we were not able to perform analyses determining risk factors for adverse outcomes. However, a recent publication based on registry data of a large cohort of patients with AIH and SARS-CoV-2 infection supports that immunosuppressive treatment is not a risk factor for mortality from COVID-19. 30 Of the 39 COVID-19 cases, the diagnosis was confirmed by nasopharyngeal swab in only 48.7% of cases. Of those patients who received confirmation of COVID-19 diagnosis by nasopharyngeal swab, a higher percentage was admitted to the hospital (Table S7) . This may reflect the health care systems' challenges in providing sufficient resources for testing of patients with mild courses of COVID-19 at the high point of the pandemic. It does, however, need to be taken into consideration that some of the COVID-19 cases in our cohort may have suffered from respiratory tract infection caused by other pathogens than SARS-CoV-2. Unfortunately, questions on whether the diagnosis was confirmed by serology were not included in the survey. Of the non-COVID-19 cases, 26.9% had one or more symptoms that are potentially compatible with COVID-19 (fever, cough, shortness of breath, smelling problems) whereas only 16.3% received a SARS-CoV-2 test. The reasons for not testing are not known but could refer to avoidance of contact to the health care system in the context of the pandemic, limited access to tests, or unwillingness. It is therefore possible, that not all COVID-19 cases were detected. Due to the patient-oriented approach, our study has inevitable limitations. First, we are not able to validate the participants' data. This limitation includes potential bias and false data. Second, since the study was announced by different channels (e.g., by patients' organizations and/or by treating physicians from healthcare centers) and due to the entry of non-personal data, we are not able to report an exact response rate for this survey. Third, questions of the survey needed to be comprehensible in order to avoid too many details and thus sources of errors. Therefore, we did not include questions on the dosage of medication, laboratory data, etc. Inherent to our study design, we were not able to analyze the mortality of COVID-19 in patients with AILD. This represents a potential bias of underreporting. Nevertheless, we are convinced that our patient-oriented survey is an important contribution to capture the situation of AILD patients in Europe during the COVID-19 pandemic since it may better reflect mild cases and those not being infected with SARS-CoV-2. Therefore, our survey adds relevant information to data from previous registry studies which focus more on severe courses of COVID-19. In summary, in our multinational Europe-wide, patient-oriented survey on COVID-19 in patients with AILD, we detected only a low rate of COVID-19 (39 of 1,779 participants, 2.2%) which is comparable to the general population. These results suggest that patients with AILD seem not to be at elevated risk of COVID-19. Coronavirus disease 2019 (COVID-19): situation report Clinical features of patients infected with 2019 novel coronavirus in Wuhan Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: A systematic review and meta-analysis Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis Predictors of in-hospital COVID-19 mortality: a comprehensive systematic review and meta-analysis exploring differences by age, sex and health conditions Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR) Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance Health status of patients with autoimmune hepatitis is not affected by the SARS-CoV-2 outbreak in Flanders Coronavirus disease 2019 in autoimmune hepatitis: a lesson from immunosuppressed patients High rates of 30-day mortality in patients with cirrhosis and COVID-19 High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: preliminary results from an international registry Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; the APCOLIS study (APASL COVID-19 Liver Injury Spectrum Study) Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study Health status of patients with autoimmune liver disease during SARS-CoV-2 outbreak in northern Italy Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review Epidemiology of autoimmune liver disease Primary sclerosing cholangitis -a comprehensive review Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis Twenty-year comparative analysis of patients with autoimmune liver diseases on transplant waitlists Epidemiology of SARS-CoV-2 COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy COVID-19 in liver transplant recipients: Preliminary data from the ELITA/ELTR registry Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study COVID-19 in an international European liver transplant recipient cohort Epidemiological pattern, incidence and outcomes of COVID-19 in liver transplant patients but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry Dexamethasone in hospitalized patients with Covid-19-preliminary report SARS-CoV-2 infection in patients with autoimmune hepatitis Prevalence of COVID-19 in patients with autoimmune liver disease in Europe: A patient-oriented online survey The authors thank the following individuals for providing trans- The authors declare that there is no conflict of interests that could be perceived as prejudicing the impartiality of the research reported. The data that support the findings of this study are available from the corresponding author upon reasonable request. https://orcid.org/0000-0001-7248-7266